Main Uses and Therapeutic Benefits

C-Time is a pharmacological formulation of Vitamin C (ascorbic acid) designed for controlled release. It is primarily used to address physiological states where the body's demand for Vitamin C exceeds dietary intake or where intestinal absorption needs to be managed over an extended period.

Treatment of Deficiency States

The primary indication for C-Time is the treatment and prevention of Vitamin C deficiency. This condition can manifest in various ways, ranging from mild fatigue and weakened connective tissues to more severe clinical presentations such as scurvy. By providing a steady supply of ascorbic acid, C-Time helps restore and maintain optimal plasma levels.

Support for Physiological Functions

Vitamin C serves as a critical cofactor in numerous biological processes. Its main benefits within the body include:

• Collagen Synthesis: Vitamin C is essential for the production of collagen, a structural protein necessary for the health and repair of skin, cartilage, tendons, ligaments, and blood vessels.
• Antioxidant Protection: It acts as a potent antioxidant, helping to protect cells from oxidative stress and neutralizing free radicals generated during normal metabolism or exposure to environmental factors.
• Immune System Function: The substance supports various cellular functions of both the innate and adaptive immune systems.
• Iron Absorption: It enhances the absorption of non-heme iron from the gastrointestinal tract, which is beneficial for maintaining healthy iron levels.

Extended-Release Advantages

Unlike standard Vitamin C supplements that are rapidly absorbed and quickly excreted by the kidneys, the C-Time delivery system is engineered to release the active ingredient gradually. This approach aims to:

• Maintain more stable concentrations of Vitamin C in the bloodstream throughout the day.
• Improve the efficiency of cellular uptake by avoiding the saturation of transport mechanisms that often occurs with high-dose, immediate-release formulations.
• Reduce the frequency of administration required to sustain therapeutic levels.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use C-Time? — Official Regulatory Information

Official government regulatory documents define specific patient populations for whom the use of a medicine is authorized, restricted, or prohibited. The decision to use C-Time is determined by a formal eligibility assessment based on these constraints.

Eligibility Structure

Classification	Populations Covered
Populations for Whom Use is Allowed	Adult patients who meet the specific condition(s) for which the medicine is formally indicated and approved by the regulatory authority.
Populations for Whom Use is Contraindicated	Individuals with a documented history of hypersensitivity or a severe allergic reaction to the active substance or any other component (excipient) of C-Time.
Populations for Whom Use is Restricted	Patients with certain pre-existing, severe, or uncontrolled medical conditions, such as severe hepatic (liver) or renal (kidney) impairment, or those in specific physiological states (e.g., pregnancy/lactation), where use may be officially prohibited or require close monitoring.

Age-Related Eligibility: Pediatric use is not established or not recommended for patients under 18 years of age unless specific safety and efficacy data for that age group are explicitly documented and approved on the product label. The official label places restrictions on use during pregnancy and lactation when documented risk or lack of safety data necessitates prohibition.

The official C-Time interaction profile is documented by global regulatory authorities and defines constraints based on its effects on co-administered substances. This profile includes a formal contraindication for co-administration with the iron-chelator Deferoxamine in patients with pre-existing impaired renal function due to the associated risk of iron-related cardiotoxicity. This high-level restriction also mandates a timing-based rule, requiring the first C-Time dose to be administered only after the initial day’s infusion of Deferoxamine.

The product is documented as an exposure-modifying substance for Ethinyl Estradiol (a component of oral contraceptives), for which regulatory data shows an increase in plasma concentration ( AUC). Separately, the profile notes a pharmacodynamic interaction where high doses may decrease the anticoagulant effect of Warfarin. This potential for reduced effectiveness is listed in official labeling.

Finally, the profile includes documented drug–food/supplement interactions stemming from its chemical reducing properties. Specifically, C-Time enhances the absorption of nonheme iron from both iron-containing medicinal products and iron-rich foods. The entire interaction structure is derived exclusively from formal regulatory statements, focusing on specific restrictions and documented exposure changes.

️ How C-Time Works: Mechanism of Action

The mechanism of C-Time (Ascorbate) is defined by its role as an essential biological reducing agent and co-factor for numerous enzymatic reactions, which influences fundamental structural and protective processes.

---

Co-Factor Action for Structural Protein Synthesis

The active molecule acts as a reducing co-factor for Fe^2+-dependent hydroxylase enzymes, such as Prolyl Hydroxylase and Lysyl Hydroxylase, regenerating their active state. This action is essential for the necessary post-translational modification (hydroxylation) of the proteins that form the collagen triple helix, thereby influencing the stability and structural integrity of connective tissues.

---

️ Direct Antioxidant and Redox Protection

Ascorbate functions as an Antioxidant by readily donating an electron to directly neutralize highly destructive Reactive Oxygen Species (ROS) and free radicals. This scavenging mechanism terminates oxidative chain reactions, which in turn shields essential cellular macromolecules like lipids, proteins, and DNA from oxidative damage, and influences redox homeostasis and cellular function.

---

Co-Factor Role in Biosynthesis and Iron Metabolism

The molecule is required as a co-factor for other metalloenzymes, including Dopamine beta-monooxygenase, and is required for the creation of the neurotransmitter norepinephrine. Furthermore, its function as a reducing agent facilitates the conversion of non-haeme Fe^3+ into the readily absorbable Fe^2+ form within the digestive tract, facilitating the body's uptake of this essential mineral.

How to Use C-Time: Official Administration Guidelines

C-Time (Sodium Ascorbate) is administered according to specific procedural guidelines, with the route and dose depending on the formulation and patient needs. These instructions define the methods for use and handling.

Approved Routes and Schedules

Administration Route	Standard Regimen
Oral (Tablet, Capsule)	Daily doses for supplementation commonly range from 50 mg to 500 mg. May be taken with or without food.
Parenteral (IV, IM, SC)	Adults and adolescents (11 years) for short-term treatment: 200 mg once daily. Maximum recommended duration is one week.

---

Procedural Instructions and Special Populations

Dosing for Children (Parenteral): Specific, lower daily doses are required for pediatric patients receiving the parenteral form, such as 50 mg once daily for ages 5 months to <12 months, and 100 mg once daily for ages 1 year to <11 years.

Preparation and IV Administration:

• The injectable solution must be diluted in a suitable infusion solution prior to use; it must not be administered as an undiluted intravenous injection.
• Administration must be via a slow intravenous infusion.
• The final prepared IV admixture should be used within 4 hours of the initial vial puncture and dilution.

These instructions define the required method of use, ensuring that the route, dose, and handling conditions are strictly adhered to.

C-Time: Recent Clinical Evidence

---

Recent clinical research concerning C-Time has primarily focused on its role as a supportive agent in immune function and its potential influence on antioxidant status, particularly in individuals with certain nutrient depletions. While earlier, foundational studies established its general safety profile, the current body of evidence is centered on understanding specific therapeutic applications and optimal supplementation contexts.

Key Findings from Controlled Trials

Several randomized controlled trials (RCTs) have explored C-Time's impact on duration and severity of common seasonal challenges. A pooled analysis of four recent trials suggests that in specific, highly-active populations, C-Time supplementation may be associated with a statistically significant reduction in the duration of these challenges, though results varied widely across studies. The effect on severity was less consistently observed, suggesting a potential role in support rather than primary treatment.

Regarding oxidative stress markers, evidence from small-scale, placebo-controlled investigations indicated that daily C-Time intake contributed to measurable changes in plasma antioxidant capacity over an eight-week period. These studies consistently reported that C-Time was generally well-tolerated across the observed dosing ranges.

Research Focus	Primary Observation (Evidence Summary)
Immune Challenge Duration	Observed reduction in duration in select groups, but not severity.
Antioxidant Status	Demonstrated an increase in plasma antioxidant markers.
Fatigue/Energy	Limited, preliminary evidence suggested a possible link to reduced perceived fatigue in certain populations.

---

Current Research Directions

Ongoing clinical work is focused on resolving the inconsistencies noted in duration-of-illness studies and is shifting toward exploring C-Time’s potential supportive role in post-exertion recovery. Researchers are also investigating optimal intake levels in individuals with chronic conditions who exhibit documented nutritional insufficiencies. The scientific community emphasizes that C-Time's evidence-based utility remains within the realm of nutritional support and not as a replacement for standard medical treatments.

Key Studies & References

1. Vitamin C and Immune Function: A Comprehensive Review

Common questions about C-Time (FAQ)

Q: Can C-Time cause bleeding or increase my risk of bruising?

Regulatory safety data notes that when taking high doses of C-Time, the active ingredient may decrease the effectiveness of the anticoagulant drug Warfarin. However, official documentation does not explicitly state that C-Time alone causes an increased risk of general bleeding or bruising.

Q: What specific serious side effects should I watch out for that might require medical attention?

Official information highlights the potential for two serious risks in susceptible individuals: the formation of kidney stones (oxalate nephropathy) and the destruction of red blood cells (acute hemolysis). Overdose symptoms that may require attention include severe abdominal pain, nausea, vomiting, or headache. If a serious adverse event or overdose is suspected, consulting a healthcare professional is appropriate.

Q: Can C-Time be used during pregnancy or while breastfeeding?

Official labeling restricts the use of C-Time during both pregnancy and lactation. There is no available data to determine the risk to an unborn child or breastfed child. Regulatory restrictions indicate that use requires consultation and professional medical direction.

Q: What should I do if I accidentally take too much C-Time (overdose)?

Overdose symptoms documented in regulatory materials may include gastrointestinal upset, diarrhea, flushing of the face, or headache. If an overdose is suspected, it is recommended to contact a poison control center or seek professional medical attention.

Q: What should I do if I accidentally get C-Time in my eye?

In the event of accidental eye contact with the product, regulatory safety data recommends rinsing the eye with plenty of water for at least 15 minutes. Medical attention may be required if the irritation persists after rinsing.

Q: Can C-Time be used to treat or cure the common cold?

According to official regulatory sources, claims that the active ingredient in C-Time is effective for preventing or treating the common cold have not been proven. The product is classified primarily as a nutritional agent.

Q: How do I know if the C-Time tablet has gone bad or expired?

The product label specifies that the medication should be used by the expiration date printed on the package. To help maintain stability, regulatory instructions indicate the product must be kept in its original container and protected from moisture and excessive heat.

How to Store and Dispose of C-Time?

C-Time (Oral Sodium Ascorbate) must be stored and disposed of according to official regulatory requirements to maintain stability and prevent environmental harm.

---

Storage Conditions

Requirement	Official Instructions
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Protect the medicine from moisture and excessive heat. Do not freeze liquid preparations.
Container	Keep C-Time in its original container and ensure the container is tightly closed when not in use.
Child Safety	The product must be stored out of the reach of children.

---

Disposal Instructions

Unused or expired C-Time should be disposed of through a drug take-back program or as advised by a pharmacist or local waste authority. It is officially restricted that the medicine must not be flushed down the toilet or poured into a drain or wastewater system.